Plasma GFAP provides a minimally invasive, accessible means for assessing astrocyte reactivity and appears to significantly moderate amyloid–tau associations across the AD spectrum and within demographically distinct cohorts. This evidence concerns the gene MAPT and Alzheimer disease.